Triage board
Triage means a quick first look at many programs to decide which ones deserve a full analysis. This one board lists every program that has passed a triage screen. Each program appears once, identified by its BPIQ drug id (BPIQ is the biotech data service we use). If a program is screened again, its row is updated, not duplicated. The most recent screen wins. This is the start of the process: the next full analysis is picked from here.
Latest screen 2026-08-11 · 3 screening run(s) saved
NOT CITABLE: for screening only
This board is a quick, low-cost ranking. It is not an analysis. Do not use any claim from this
board in a program analysis unless it is checked again there (framework/02-connectors.md § Triage
pass). The board is only for deciding what to analyse next. It does not support a claim by itself.
On the board
140
still current
Screened
130
not yet decided
Shortlisted
0
waiting for a full analysis
Analysed
10
full analysis done
Dismissed
0
ruled out
Candidates
Sorted by catalyst date (the date of the big event), earliest first, then by tier (A is best)
| State | Candidate | Catalyst | Signals | Flags | Actions |
|---|---|---|---|---|---|
| Analysed | A | October 19, 2026 exact day given 0 delays | N/A $58M market cap
| in no hfs | |
| Screened | A EVAX EVX-01 + pembrolizumab Melanoma | October 24, 2026 exact day given 0 delays | N/A $25M market cap
| — | |
| Analysed | B | October 24, 2026 exact day given 5 delays | OK $343M market cap
| in top10 hfs | |
| Screened | C AGEN Botensilimab/Balstilimab (BOT/BAL) Neoadjuvant dMMR colorectal cancer | October 25, 2026 exact day given 0 delays | EXPIRED $312M market cap
| in no hfs | |
| Analysed | B | October 2026 only the month given 1 delay | OK $2.03B market cap
| high mgmt interest | |
| Screened | C GUTS Revita (DMR) Obesity / T2D (REMAIN-1 pivotal 6-month) | Early Q4 2026 rough period (placeholder) 1 delay | TIGHT $109M market cap
| high mgmt interest | |
| Analysed | A | Fall 2026 only the month given 2 delays | OK $1B market cap
| big mover high mgmt interest | |
| Screened | A PEPG PGN-EDODM1 Myotonic dystrophy type 1 (FREEDOM2, 10mg MAD) | November 2026 only the month given 2 delays | OK $137M market cap
| high mgmt interest | |
| Analysed | A | YE 2026 rough period (placeholder) 0 delays | OK $190M market cap
| high mgmt interest | |
| Analysed | A | H2 2026 rough period (placeholder) 1 delay | N/A $1.06B market cap
| suspected mover hedge fund pick high mgmt interest in top10 hfs | |
| Screened | A RZLT Ersodetug Tumor hyperinsulinism (upLIFT) | H2 2026 rough period (placeholder) 0 delays | OK $454M market cap
| big mover | |
| Screened | A IMTX ACTengine IMA203 GEN1 (PRAME) Cutaneous melanoma (SUPRAME) | 2026 rough period (placeholder) 0 delays | OK $1.18B market cap
| suspected mover high mgmt interest | |
| Screened | A ANNX Vonaprument (ANX007, IVT) Geographic atrophy (ARCHER II) | H2 2026 rough period (placeholder) 1 delay | OK $834M market cap
| high mgmt interest | |
| Screened | A VIR Tobevibart + elebsiran Hepatitis delta (ECLIPSE 1) | Q4 2026 rough period (placeholder) 1 delay | OK $1.46B market cap
| suspected mover high mgmt interest | |
| Screened | A CRVS Soquelitinib (CPI-818) Peripheral T-cell lymphoma (interim) | Late 2026 rough period (placeholder) 1 delay | OK $1.12B market cap
| in top10 hfs | |
| Screened | A TARA IV choline chloride Intestinal-failure-associated liver disease (THRIVE-3 interim) | H2 2026 rough period (placeholder) 0 delays | OK $220M market cap
| — | |
| Screened | A SLGL SGT-610 (patidegib) Gorlin syndrome | Q4 2026 rough period (placeholder) 0 delays | N/A $268M market cap
| — | |
| Screened | A MNOV MN-166 (ibudilast) ALS (COMBAT-ALS) | YE 2026 rough period (placeholder) 0 delays | OK $65M market cap
| — | |
| Screened | A DMAC DM199 (rinvecalinase alfa) Acute ischemic stroke (ReMEDy2 interim) | H2 2026 rough period (placeholder) 0 delays | OK $341M market cap
| suspected mover hedge fund avoid high mgmt interest | |
| Analysed | A | H2 2026 rough period (placeholder) 1 delay | OK $131M market cap
| high mgmt interest | |
| Screened | A VTVT Cadisegliatin (TTP399) Type 1 diabetes (CATT1) | H2 2026 rough period (placeholder) 0 delays | N/A $127M market cap
| high mgmt interest | |
| Screened | A AGMB Ontunisertib (AGMB-129) Fibrostenosing Crohn's disease | H2 2026 rough period (placeholder) 0 delays | OK $705M market cap
| — | |
| Screened | A BMEA BMF-219 (icovamenib) + GLP-1 Severe insulin-deficient T2D (COVALENT-211) | Q4 2026 rough period (placeholder) 0 delays | OK $90M market cap
| high mgmt interest | |
| Screened | A CLYM Budoprutug Primary membranous nephropathy (PrisMN) | Q4 2026 rough period (placeholder) 0 delays | OK $714M market cap
| big mover hedge fund avoid in no hfs | |
| Screened | A ENGN Detalimogene (EG-70) Non-muscle invasive bladder cancer (LEGEND) | H2 2026 rough period (placeholder) 0 delays | OK $121M market cap
| high mgmt interest in top10 hfs | |
| Screened | A GNLX Olvi-Vec Small cell lung cancer (China, systemic) | 2026 rough period (placeholder) 0 delays | OK $113M market cap
| in no hfs | |
| Screened | A GNLX Olvi-Vec NSCLC (VIRO-25, systemic) | 2026 rough period (placeholder) 0 delays | OK $113M market cap
| in no hfs | |
| Screened | A INKT AgenT-797 +/- pembrolizumab/nivolumab Relapsed/refractory solid tumors | 2026 rough period (placeholder) 0 delays | OK $58M market cap
| in no hfs | |
| Screened | A INKT AgenT-797 Acute respiratory disease syndrome / ARDS | H2 2026 rough period (placeholder) 0 delays | OK $58M market cap
| high mgmt interest in no hfs | |
| Screened | A KYTX KYV-101 Rheumatoid arthritis (IIT) | 2026 rough period (placeholder) 0 delays | OK $464M market cap
| — | |
| Screened | A MAZE MZE829 (APOL1 inhibitor) APOL1-mediated kidney disease | Q4 2026 rough period (placeholder) 0 delays | OK $1.54B market cap
| suspected mover hedge fund pick high mgmt interest in top10 hfs | |
| Screened | A MNOV MN-166 (ibudilast) Chemotherapy-induced peripheral neuropathy (OXTOX) | H2 2026 rough period (placeholder) 0 delays | OK $65M market cap
| in no hfs | |
| Screened | A PCRX PCRX-201 (enekinragene inzadenovec) Knee osteoarthritis (ASCEND Part A) | YE 2026 rough period (placeholder) 0 delays | N/A $991M market cap
| in no hfs | |
| Screened | A PHAR Leniolisib Immunodeficiency (broader PID) | H2 2026 rough period (placeholder) 1 delay | OK $756M market cap
| suspected mover hedge fund avoid in no hfs | |
| Screened | A QTTB Bempikibart (ADX-914) Alopecia areata (Ph2a) | H2 2026 rough period (placeholder) 0 delays | OK $491M market cap
| high mgmt interest | |
| Screened | A SLS SLS009 (GFH009) Frontline high-risk AML | Q4 2026 rough period (placeholder) 0 delays | OK $2.33B market cap
| in no hfs | |
| Screened | A SNSE Piktor (PI3K/mTOR inhibitor) Advanced endometrial cancer (FTH-PIK-201) | YE 2026 rough period (placeholder) 0 delays | OK $19M market cap
| — | |
| Screened | A TLSA Intranasal Foralumab Alzheimer's disease | 2026 rough period (placeholder) 0 delays | N/A $126M market cap
| in no hfs | |
| Screened | A ZBIO Obexelimab Systemic lupus erythematosus (SunStone) | Q4 2026 rough period (placeholder) 1 delay | OK $1.96B market cap
| suspected mover high mgmt interest | |
| Screened | A ZURA Tibulizumab Hidradenitis suppurativa (TibuSHIELD) | Q4 2026 rough period (placeholder) 0 delays | OK $535M market cap
| — | |
| Screened | B IPHA Monalizumab + durvalumab NSCLC (PACIFIC-9) | H2 2026 rough period (placeholder) 0 delays | N/A $164M market cap
| high mgmt interest | |
| Screened | B HCM ORPATHYS (savolitinib) + TAGRISSO NSCLC (SAFFRON) | H2 2026 rough period (placeholder) 0 delays | N/A $1.93B market cap
| suspected mover hedge fund avoid high mgmt interest | |
| Screened | B IMCR KIMMTRAK (tebentafusp) +/- anti-PD1 2L+ cutaneous melanoma (TEBE-AM) | 2026 rough period (placeholder) 0 delays | OK $1.72B market cap
| in top10 hfs | |
| Screened | B KOD KSI-101 Macular edema secondary to inflammation (PEAK) | Q4 2026 rough period (placeholder) 0 delays | OK $2.6B market cap
| high mgmt interest | |
| Screened | B IRON Bitopertin Erythropoietic protoporphyria (APOLLO) | Q4 2026 rough period (placeholder) 0 delays | OK $2.96B market cap
| high mgmt interest in top10 hfs | |
| Screened | B KPTI XPOVIO (selinexor) + pomalidomide + dex Multiple myeloma (XPORT-MM-031) | H2 2026 rough period (placeholder) 0 delays | OK $43M market cap
| — | |
| Screened | B HRMY WAKIX (pitolisant) Prader-Willi EDS (TEMPO) | H2 2026 rough period (placeholder) 0 delays | N/A $2.04B market cap
| — | |
| Screened | B PCRX ZILRETTA (triamcinolone acetonide) Shoulder osteoarthritis | Q4 2026 rough period (placeholder) 0 delays | N/A $1.04B market cap
| suspected mover hedge fund avoid high mgmt interest | |
| Screened | B VNDA NEREUS (tradipitant) GLP-1-induced nausea and vomiting (Thetis) | Q4 2026 rough period (placeholder) 0 delays | OK $306M market cap
| — | |
| Screened | B VNDA Bysanti (milsaperidone) Adjunctive major depressive disorder | 2026 rough period (placeholder) 0 delays | OK $306M market cap
| — | |
| Screened | B VNDA VQW-765 Social anxiety disorder | YE 2026 rough period (placeholder) 0 delays | OK $306M market cap
| — | |
| Screened | B XOMA Ersodetug Tumor hyperinsulinism (upLIFT) | H2 2026 rough period (placeholder) 0 delays | N/A $710M market cap
| suspected mover high mgmt interest | |
| Screened | B BCYC Zelenectide pevedotin (BT8009) Urothelial cancer (Duravelo-2) | H2 2026 rough period (placeholder) 1 delay | OK $269M market cap
| — | |
| Screened | B EIKN EIK1001 1L advanced melanoma (TeLuRide-006 first interim) | H2 2026 rough period (placeholder) 0 delays | OK $498M market cap
| — | |
| Screened | B EIKN EIK1001 Stage 4 NSCLC (TeLuRide-008) | H2 2026 rough period (placeholder) 0 delays | OK $498M market cap
| — | |
| Screened | B LYEL Ronde-cel (LYL314) Large B-cell lymphoma (PiNACLE) | H2 2026 rough period (placeholder) 0 delays | OK $317M market cap
| high mgmt interest | |
| Screened | B ACIU ACI-7104.056 Parkinson's disease (VacSYn Part 1) | H2 2026 rough period (placeholder) 1 delay | N/A $233M market cap
| big mover high mgmt interest | |
| Screened | B ADAG Neoadjuvant Muzastotug (ADG126) Colorectal cancer (neoadjuvant, IIT) | 2026 rough period (placeholder) 0 delays | N/A $279M market cap
| in no hfs | |
| Screened | B ADCT ZYNLONTA + Rituximab Follicular lymphoma / MZL (IIT) | YE 2026/Mid-2027 rough period (placeholder) 0 delays | OK $144M market cap
| — | |
| Screened | B ADCT ZYNLONTA Marginal zone lymphoma (IIT) | YE 2026/Mid-2027 rough period (placeholder) 0 delays | OK $144M market cap
| — | |
| Screened | B ANAB Jemperli/Dostarlimab Locally advanced dMMR/MSI-H rectal cancer (AZUR-1) | H2 2026 rough period (placeholder) 0 delays | OK $1.63B market cap
| — | |
| Screened | B ANAB Jemperli/Dostarlimab Stage III MMRp/MSS resectable colon cancer (AZUR-4) | Q4 2026 rough period (placeholder) 0 delays | OK $1.63B market cap
| — | |
| Screened | B BMEA Icovamenib + GLP-1 Type 2 diabetes (COVALENT-212) | Q4 2026 rough period (placeholder) 0 delays | OK $90M market cap
| — | |
| Screened | B COAG Sutacimig (HMB-001) Congenital Factor VII deficiency | Late 2026/Early 2027 rough period (placeholder) 0 delays | OK $2.34B market cap
| in no hfs | |
| Screened | B COYA COYA 301 (low-dose IL-2) Alzheimer's disease | H2 2026 rough period (placeholder) 0 delays | OK $107M market cap
| — | |
| Screened | B FGEN FG-3246 (ADC) Metastatic castration-resistant prostate cancer | H2 2026 rough period (placeholder) 0 delays | OK $39M market cap
| high mgmt interest | |
| Screened | B FGEN FG-3180 (CD46 PET tracer) mCRPC companion diagnostic | H2 2026 rough period (placeholder) 0 delays | OK $39M market cap
| — | |
| Screened | B IFRX Izicopan Chronic spontaneous urticaria (Ph2a) | 2026 rough period (placeholder) 0 delays | OK $261M market cap
| — | |
| Screened | B IFRX Izicopan Hidradenitis suppurativa (Ph2a) | 2026 rough period (placeholder) 0 delays | OK $261M market cap
| — | |
| Screened | B IMAB Uliledlimab (TJD5) NSCLC (+/- toripalimab, pembrolizumab) | 2026 rough period (placeholder) 0 delays | N/A $534M market cap
| in no hfs | |
| Screened | B IOVA Iovance TIL (LN-145) NSCLC (2L, IOV-LUN-202) | 2026 rough period (placeholder) 0 delays | OK $1.94B market cap
| — | |
| Screened | B KPTI XPOVIO (selinexor) Myelofibrosis (SENTRY-2) / ITP | H2 2026 rough period (placeholder) 0 delays | OK $43M market cap
| — | |
| Screened | B KYTX KYV-101 Myasthenia gravis (KYSA-6) | H2 2026 rough period (placeholder) 0 delays | OK $464M market cap
| — | |
| Screened | B NKTR Rezpegaldesleukin (NKTR-358) Alopecia areata (REZOLVE-AA, 24-wk off-treatment) | Q4 2026 rough period (placeholder) 0 delays | OK $2.47B market cap
| — | |
| Screened | B PHAT VOQUEZNA (vonoprazan) Eosinophilic esophagitis (pHalcon-EoE-201) | Q4 2026 rough period (placeholder) 0 delays | OK $666M market cap
| — | |
| Screened | B REPL RP2 + atezolizumab + bevacizumab Hepatocellular carcinoma | Q4 2026 rough period (placeholder) 0 delays | OK $994M market cap
| — | |
| Screened | B SNDX Axatilimab (Niktimvo) + ruxolitinib Newly diagnosed chronic GVHD | Q4 2026 rough period (placeholder) 0 delays | OK $1.78B market cap
| suspected mover high mgmt interest | |
| Screened | B SNDX Axatilimab Idiopathic pulmonary fibrosis (MAXPIRe) | Q4 2026 rough period (placeholder) 0 delays | OK $1.78B market cap
| — | |
| Screened | B SPRY neffy (epinephrine nasal spray) Acute flares in chronic spontaneous urticaria | Q4 2026 rough period (placeholder) 0 delays | OK $532M market cap
| suspected mover high mgmt interest | |
| Screened | B TNXP TNX-102 SL (Tonmya) Acute stress reaction/disorder (OASIS, DoD-funded) | H2 2026 rough period (placeholder) 0 delays | OK $179M market cap
| in no hfs | |
| Screened | B TYRA TYRA-200 Intrahepatic cholangiocarcinoma | Q4 2026 rough period (placeholder) 0 delays | OK $1.53B market cap
| in top10 hfs | |
| Screened | B XNCR XmAb942 Inflammatory bowel disease (XENITH-UC interim) | YE 2026 rough period (placeholder) 0 delays | OK $1.47B market cap
| suspected mover hedge fund pick high mgmt interest in top10 hfs | |
| Analysed | B | YE 2026 rough period (placeholder) 0 delays | OK $352M market cap
| big mover high mgmt interest | |
| Screened | C RGNX ABBV-RGX-314 (subretinal) Wet AMD (ATMOSPHERE/ASCENT) | Q4 2026 rough period (placeholder) 0 delays | SHORT $620M market cap
| suspected mover high mgmt interest | |
| Screened | C BHVN Opakalim (BHV-7000) Focal epilepsy (RISE3) | H2 2026 rough period (placeholder) 2 delays | SHORT $2.03B market cap
| high mgmt interest | |
| Screened | C MBRX Annamycin + cytarabine R/R AML (MIRACLE Part A) | December 2026-February 2027 only the month given 3 delays | SHORT $2M market cap
| — | |
| Analysed | C | Late 2026 rough period (placeholder) 0 delays | EXPIRED $165M market cap
| — | |
| Screened | C ACRS Bosakitug (ATI-045) Atopic dermatitis (Ph2) | Q4 2026 rough period (placeholder) 0 delays | EXPIRED $888M market cap
| suspected mover hedge fund pick in top10 hfs | |
| Screened | C ATAI VLS-01 (buccal DMT) Treatment-resistant depression (Elumina) | Q4 2026 rough period (placeholder) 1 delay | EXPIRED $2.66B market cap
| high mgmt interest | |
| Screened | C ATOS (Z)-Endoxifen Metastatic breast cancer | 2026 rough period (placeholder) 0 delays | TIGHT $24M market cap
| in no hfs | |
| Screened | C AURA Belzupacap Sarotalocan (bel-sar) Metastases to the choroid | 2026 (est) rough period (placeholder) 0 delays | SHORT $799M market cap
| — | |
| Screened | C BHVN Taldefgrobep alfa (BHV-2000) Obesity | H2 2026 rough period (placeholder) 0 delays | EXPIRED $2.17B market cap
| — | |
| Screened | C BIOA BGE-102 Obesity (cardiovascular-risk POC) | H2 2026 rough period (placeholder) 0 delays | EXPIRED $517M market cap
| — | |
| Screened | C BLRX Motixafortide (BL-8040) + cemiplimab Pancreatic cancer (CheMo4METPANC) | 2026 rough period (placeholder) 0 delays | EXPIRED $12M market cap
| in no hfs | |
| Screened | C CRIS Emavusertib (CA-4948) Chronic lymphocytic leukemia (TakeAim CLL) | December 2026 only the month given 0 delays | EXPIRED $8.9M market cap
| — | |
| Screened | C FBRX FB102 Celiac disease | 2026 rough period (placeholder) 0 delays | TIGHT $1.57B market cap
| big mover high mgmt interest | |
| Screened | C LTRN LP-300 EGFR Exon-21 L858R NSCLC (HARMONIC) | H2 2026 rough period (placeholder) 0 delays | EXPIRED $36M market cap
| in no hfs | |
| Screened | C OGEN ONP-002 Traumatic brain injury (Ph2a, Australia) | YE 2026 rough period (placeholder) 1 delay | SHORT $2.4M market cap
| in no hfs | |
| Screened | C ONCY Pelareorep + bevacizumab + FOLFIRI 2L KRAS-mutant MSS metastatic colorectal cancer | Q4 2026 rough period (placeholder) 0 delays | EXPIRED $95M market cap
| in no hfs | |
| Screened | C PTN Bremelanotide + PDE5i Erectile dysfunction | H2 2026 rough period (placeholder) 0 delays | EXPIRED $14M market cap
| — | |
| Screened | D XFOR Mavorixafor Chronic/severe congenital neutropenia (4WARD) | H2 2026 rough period (placeholder) 1 delay | OK $375M market cap
| — | |
| Screened | D MDWD EscharEx Venous leg ulcers (VALUE) | Q4 2026 rough period (placeholder) 0 delays | OK $181M market cap
| high mgmt interest | |
| Screened | D RFL Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) Niemann-Pick C1 (TransportNPC) | H2 2026 rough period (placeholder) 0 delays | OK $100M market cap
| high mgmt interest | |
| Screened | D MDNAF MDNA55 (bizaxofusp) Recurrent glioblastoma (Ph2b) | Q4 2026 rough period (placeholder) 0 delays | EXPIRED $25M market cap
| in no hfs | |
| Screened | D SKYE Nimacimab Obesity (CBeyond Part C) | Q4 2026 rough period (placeholder) 1 delay | EXPIRED $20M market cap
| — | |
| Screened | A CGTX Zervimesine (CT1812) Alzheimer's disease (SHINE registrational read-through) | 2027 rough period (placeholder) 0 delays | OK $95M market cap
| in no hfs | |
| Screened | A AVIR Bemnifosbuvir + ruzasvir Hepatitis C (C-FORWARD) | Early 2027 rough period (placeholder) 1 delay | OK $376M market cap
| suspected mover high mgmt interest | |
| Screened | A TECX TX45 Pulmonary hypertension in HFpEF (APEX) | Early Q1 2027 rough period (placeholder) 1 delay | OK $558M market cap
| suspected mover high mgmt interest | |
| Screened | A LXRX ZYNQUISTA (sotagliflozin) Hypertrophic cardiomyopathy (SONATA-HCM) | Q1 2027 rough period (placeholder) 0 delays | OK $1.03B market cap
| — | |
| Screened | A ATXS Navenibart (STAR-0215) Hereditary angioedema (ALPHA-ORBIT) | Early 2027 rough period (placeholder) 0 delays | OK $718M market cap
| high mgmt interest | |
| Screened | A COYA COYA 302 ALS (ALSTARS) | Q1 2027 rough period (placeholder) 0 delays | OK $107M market cap
| — | |
| Screened | B TYRA Dabogratinib (TYRA-300) Pediatric achondroplasia (BEACH301) | End Of Q1 2027 rough period (placeholder) 1 delay | OK $1.53B market cap
| in top10 hfs | |
| Screened | C ANVS Buntanetap (ANVS401) Early Alzheimer's disease | Q1 2027 rough period (placeholder) 0 delays | SHORT $74M market cap
| — | |
| Screened | C PSTV REYOBIQ Glioblastoma (ReSPECT-GBM) | Q1 2027 rough period (placeholder) 0 delays | EXPIRED $27M market cap
| in no hfs | |
| Screened | C QNCX Rapamycin/Sirolimus (LAM-001) Bronchiolitis obliterans syndrome | Q1 2027 rough period (placeholder) 0 delays | EXPIRED $28M market cap
| — | |
| Screened | D REPL RP2 + Opdivo Uveal melanoma (REVEAL) | Q1 2027 rough period (placeholder) 0 delays | OK $941M market cap
| — | |
| Screened | D QNCX Sirolimus/Rapamycin (LAM-001) Bronchiolitis obliterans syndrome (duplicate BPIQ row) | Q1 2027 rough period (placeholder) 0 delays | EXPIRED $28M market cap
| — | |
| Screened | A VOR Telitacicept Myasthenia gravis (UPSTREAM MG) | H1 2027 rough period (placeholder) 0 delays | OK $1.15B market cap
| high mgmt interest | |
| Screened | A NBTX NBTXR3 (JNJ-1900) +/- cetuximab Head and neck cancer (NANORAY-312) | H1 2027 rough period (placeholder) 0 delays | N/A $1.95B market cap
| — | |
| Screened | A ADAG Muzastotug (ADG126) + Keytruda Advanced MSS colorectal cancer | H1 2027 rough period (placeholder) 0 delays | N/A $279M market cap
| in no hfs | |
| Screened | A ANRO ALTO-300 Adjunctive major depressive disorder | H1 2027 rough period (placeholder) 1 delay | OK $999M market cap
| — | |
| Screened | A KROS KER-065 (rinvatercept) Duchenne muscular dystrophy | H1 2027 rough period (placeholder) 0 delays | OK $198M market cap
| — | |
| Screened | A MGTX AAV2-hAQP1 Radiation-induced xerostomia (AQUAx2) | Q2 2027 rough period (placeholder) 0 delays | N/A $1.16B market cap
| — | |
| Screened | A SPTX GlyphAllo (SPT-300) Major depressive disorder (BUOY-1) | H1 2027 rough period (placeholder) 0 delays | OK $1.2B market cap
| in no hfs | |
| Screened | A TARS TP-05 Lyme disease prevention (Calliope) | H1 2027 rough period (placeholder) 0 delays | OK $2.67B market cap
| — | |
| Screened | A TARS TP-04 Ocular rosacea | H1 2027 rough period (placeholder) 1 delay | OK $2.67B market cap
| — | |
| Screened | A ZURA Tibulizumab (ZB-106) Systemic sclerosis (TibuSURE) | H1 2027 rough period (placeholder) 0 delays | OK $535M market cap
| — | |
| Screened | B HRMY EPX-100 (clemizole) Dravet syndrome (ARGUS) | H1 2027 rough period (placeholder) 1 delay | N/A $2.04B market cap
| — | |
| Screened | B HRMY EPX-100 (clemizole) Lennox-Gastaut syndrome (LIGHTHOUSE) | H1 2027 rough period (placeholder) 1 delay | N/A $2.04B market cap
| — | |
| Analysed | B | H1 2027 rough period (placeholder) 0 delays | SHORT $2.45B market cap
| — | |
| Screened | B PRTA BMS-986446 (PRX005) Early Alzheimer's disease (TargetTau-1) | H1 2027 rough period (placeholder) 0 delays | N/A $444M market cap
| — | |
| Screened | B RXRX REC-4881 Cancer (LILAC, biomarker-selected) | H1 2027 rough period (placeholder) 0 delays | OK $1.68B market cap
| — | |
| Screened | C PROK Rilparencel (REACT) Diabetic CKD (PROACT-1) | Q2 2027 rough period (placeholder) 0 delays | TIGHT $465M market cap
| high mgmt interest | |
| Screened | C ADVM Ixo-vec (ADVM-022) Wet AMD (ARTEMIS) | H1 2027 rough period (placeholder) 0 delays | EXPIRED $96M market cap
| — | |
| Screened | C ENLV Allocetra Knee osteoarthritis (Ph2b) | Q2 2027 rough period (placeholder) 0 delays | EXPIRED $37M market cap
| in no hfs | |
| Screened | C JUNS JOTROL (resveratrol) Parkinson's disease (RESET) | H1 2027 rough period (placeholder) 0 delays | EXPIRED $4.4M market cap
| in no hfs | |
| Screened | C KARD Ataciguat Moderate calcific aortic valve stenosis (KATALYST-AV) | H1 2027 rough period (placeholder) 0 delays | SHORT $1.81B market cap
| in no hfs | |
| Screened | C KARD Tonlamarsen Acute severe hypertension / post-hospitalization BP | H1 2027 rough period (placeholder) 0 delays | SHORT $1.81B market cap
| in no hfs | |
| Screened | C KARD Danicamtiv Genetic/familial dilated cardiomyopathy (KINSHIP-DCM) | H1 2027 rough period (placeholder) 0 delays | SHORT $1.81B market cap
| in no hfs | |
| Screened | D MGNX Lorigerlimab monotherapy Platinum-resistant ovarian / clear-cell gynecologic cancer (LINNET) | H1 2027 rough period (placeholder) 1 delay | EXPIRED $248M market cap
| — | |
| No candidates match the filters you chose. | |||||
Want to see what happened to candidates that have left this board? See the archive →
Screen provenance
For each screening run: the filters used, the set of companies searched, known data errors and missing data. This is for checking our work, not for ranking.
Run 2026-08-11 catalyst dates 2026-08 to 2026-09▾
Screening only, per framework/06-prompts.md § Triage and framework/02-connectors.md § Triage pass. No claim here may enter an analysis without being re-verified there.
Companies searched
Filters used
market capitalisation <= $3,000,000,000 USD; catalyst is a Phase 2 data readout; window 2026-08 to 2026-09, effective 2026-08-11 through 2026-09-30 (a catalyst already past does not qualify)
Missing data
- fetch_all_upcoming_catalysts was used as the stage-and-date pre-filter over drug ids per 02-connectors.md § Triage pass step 2. It terminated NATURALLY at 828 unique rows (last page returned 78 of a possible 250, and offset 1000 returned empty) rather than at a page cap, so it is treated as complete for this run. fetch_company_drugs was called only on the 16 tickers this pre-filter surfaced, never on all 572 tickers under the cap, so a qualifying Phase 2 readout at a company never named as furthest_drug/next_drug_catalyst/next_bigmover_drug_catalyst by ANY id in the 828-row feed would not have been reached at all. This run did not surface a case of that (unlike 2026-08-07's KARD case, which found an extra qualifying row within an already-resolved ticker), but that is not proof none exists -- it is a structural blind spot of the method, not a property of this particular universe.
- The stage_label filter was drawn narrowly, matching the 2026-08-07 precedent: only 'Phase 2', 'Phase 2a' and 'Phase 2b' were kept as 'Phase 2 data readout'. Combined-phase 'Phase 1/2' and 'Phase 2/3' trials were excluded even where event_label was 'Data readout' and the date sat inside the window. All 8 such rows are logged in excluded (exhaustive for this window, not a sample). A caller who intended those to count would need a re-run with a broader stage_label list; step_6 in method quantifies how much the ranked count moves under a narrower reading in the other direction.
- No market-cap floor was applied, since the caller specified none. Rows below include micro-caps under $30M (ALZN $6.6M, BIVI $7.5M, LGVN $24.2M, CNSY $26.4M).
- Triage does not call CT.gov, PubMed, Open Targets, ChEMBL or web search. Every catalyst date, enrollment figure and safety note below is BPIQ's own, read only against the note field in the same record -- none of it is independently verified and none of it is citable in an analysis without being re-checked there.
- 'slips' was counted qualitatively from reading each company's note changelog during the per-ticker sweep, the same method the 2026-08-04 and 2026-08-07 screens used, rather than a mechanical string-diff. A second reviewer could reasonably differ by one slip on a row where a narrowing (a quarter or season specified down to an exact day, or vice-versa) is arguably a specification rather than a genuine change; flagged in the row's own comment where it mattered (CNSY, TLSA, IRON).
- The caller-reported website figure of 12 companies for this same filter could not be reproduced exactly from data available to this run. The closest reconciliation found is 11 companies under a strict stage_label=='Phase 2' reading (one short of 12, see method step_6); the excluded list below carries every candidate explanation checked -- the four above-cap companies, the one just-above-cap company (ALMS), the eight combined-phase rows, the one just-outside-window company (SXTP), and the one label/date-conflict row (BIVI) -- so the orchestrator can test other combinations without re-running the sweep.
Data errors seen in the data connectors
- fetch_all_upcoming_catalysts ignored start_date/end_date exactly as 02-connectors.md documents (neither was passed this run, since passing them was already known to be pointless): the feed's first page began at catalyst_date 2026-08-10, one day before this run's own window start, and rows ascend monotonically by catalyst_date through 2029-12-31 before a 78-row null-catalyst_date tail closes the feed at 828 total rows.
- catalyst_date is synthesized from period text on the large majority of qualifying rows (e.g. 'Mid-2026' -> 2026-08-15, 'Q3 2026' -> 2026-09-30, 'Summer 2026' -> 2026-08-31, 'Late Summer 2026' -> 2026-08-31). Only 1 of 17 qualifying rows (CNSY 15204, 'August 13, 2026') names an exact day.
- The company screener's furthest_drug/next_drug_catalyst/next_bigmover_drug_catalyst id-join fields missed 6 of the pre-filter's 22 ids outright: the four above-cap companies (resolved anyway via catalyst_source, so cost nothing here) plus CNTB's second qualifying row. Every ticker this run actually needed was still reachable, but only because the catalyst_source URL fallback worked on all 6 -- a row whose catalyst_source were also blank or unparseable (as 17051/CHRS's was, until the id-join itself resolved it) would have been lost entirely.
- Two rows describing what reads as the same underlying event -- argenx's efgartigimod/VYVGART myositis data -- are filed under two different companies: ARGX (id 18163, the originator) and ZLAB (id 20688, Zai Lab, argenx's China-market partner). Both fall outside this screen on stage grounds (Phase 2/3) so it did not need resolving here, but it is the 'one row can cover two things' bug the corpus already tracks, on a cross-company axis rather than within one company.
- BioVie's SUNRISE-PD (Bezisterim, early Parkinson's, id 17384): the note reports its own topline result directly ('08/06/26:- SUNRISE-PD topline Ph2b results reported; met endpoints') while stage_event_label still reads 'Phase 2b Update' rather than 'Data readout', has_catalyst remains true, and catalyst_date/catalyst_date_text are null/'TBA'. The structured fields never caught up to the event the note already describes. Logged in excluded.
- Rein Therapeutics (RNTX, id 18014): the company-tier cash_runway_end_date (2026-07-25, already in the past as of this 2026-08-11 run) directly contradicts the program-tier note's own more recent claim (05/18/26) that 'Financing closed; expects to fund RENEW Ph2 through completion; cash runway into Q1 2028.' Neither field was updated to match the other as of this run; flagged rather than resolved.
Left out
- ARGX (17511) — Empasiprubart — argenx is far above the $3B cap ($53.79B); resolved via catalyst_source URL company name, not the id-join fields.
- ACAD (17283) — ACP-204 — ACADIA Pharmaceuticals is above the $3B cap ($5.03B); resolved via catalyst_source URL company name.
- SYRE (18848) — SPY003 — Spyre Therapeutics is above the $3B cap ($9.25B); resolved via catalyst_source URL company name.
- SYRE (19043) — SPY072 (SPY002-072) — Same company and cap reason as SPY003 above -- Spyre's second qualifying id in this window.
- ALMS (18878) — ESK-001 — Alumis is just above the $3B cap ($3.52B, ~17% over) -- the closest above-cap near-miss found in this screen; no company anywhere sits between $3.0B and $3.1B (checked directly).
- CHRS (17051) — Toripalimab +/- CHS-006 (anti-TIGIT) — stage_label is 'Phase 1/2', excluded by this run's narrow reading of 'Phase 2 data readout'. Coherus is well within the cap ($196M).
- AURA (17079) — Belzupacap Sarotalocan (Bel-sar / AU-011) — stage_label is 'Phase 1/2', same narrow-reading exclusion ($826M market cap).
- CLRB (18881) — CLR 121125 — stage_label is 'Phase 1/2', same narrow-reading exclusion.
- CLRB (19077) — CLR 125 — stage_label is 'Phase 1/2', same narrow-reading exclusion -- Cellectar's second qualifying id in this window.
- BEAM (18113) — BEAM-302 — stage_label is 'Phase 1/2' (first patient just dosed in the 'global pivotal cohort' per the 08/04/26 release), same narrow-reading exclusion. Day-precise date; market cap close to the cap at $2.84B.
- OCGN (17593) — OCU410ST — stage_label is 'Phase 2/3', same narrow-reading exclusion.
- ARGX (18163) — Efgartigimod (myositis) — stage_label is 'Phase 2/3'; also above the cap on its own (see the Empasiprubart row above) -- excluded on both grounds.
- ZLAB (20688) — VYVGART/Efgartigimod Alfa (myositis) — stage_label is 'Phase 2/3', same narrow-reading exclusion. Zai Lab is the China-market partner filing what reads as the same underlying efgartigimod myositis data as argenx's row above ($2.62B, close to the cap).
- SXTP (17696) — Arakoda (Tafenoquine) -- Babesiosis — Interim babesiosis data guided for October 6, 2026 -- 6 days after this window's 2026-09-30 close, the closest date-based near-miss found in this screen. Also carries an EXPIRED cash_runway_end_date (2026-07-18, already past this run's own date) on cash of $3.3M.
- BIVI (17384) — Bezisterim (NE3107) -- SUNRISE-PD, early Parkinson's — has_catalyst:true with no catalyst_date, but the note reports topline results already delivered 08/06/26 ('met endpoints'); stage_event_label still reads 'Phase 2b Update', not 'Data readout', so it fails both the date test and the event-label test. A screener reading note text rather than structured fields could plausibly still count this one.
Legend
- precision:
- DAY = catalyst_date_text names a day. MONTH = names a month or a season (Summer/Fall/Winter/Spring), per the schema's own wording -- 'Summer 2026' and 'Late Summer 2026' are both classified MONTH here, distinct from a quarter or half modified the same way ('Late Q3 2026' stays PERIOD). PERIOD = half, quarter or year only (including one modified by early/late/mid); catalyst_date is synthesized by BPIQ. UNKNOWN = no date disclosed at all.
- slips:
- Count of distinct changes to the guided timing visible in the note changelog actually read during this sweep, including narrowings/specifications as well as delays, and one deliberate pull-in (IRON, 'moved up to Q3 2026'). 0 means the guidance was stable, or only seen once, across the updates read -- not that no changelog exists. A second reviewer could differ by one on rows flagged in their own comment.
- runway_vs_catalyst:
- EXPIRED = cash_runway_end_date is more than ~1 month before this row's own catalyst_date. Four rows carry a cash_runway_end_date already before the 2026-08-11 run date itself: OSTX, ALZN and the excluded near-miss SXTP genuinely so; RNTX's field also reads EXPIRED but its own note directly contradicts it (see comment and connector_bugs_observed). SHORT = up to ~1 month before. TIGHT = within ~1 month after (BIVI, 5 days). OK = comfortably after. N/A = null or a far-future sentinel (year >= 2100).
- tier:
- A = clean, funded (OK/N/A runway), materially binary for the company reading it out, no specific red flag surfaced in the sweep. B = a real readout but diluted materiality: a correlated sister program at the same company already counted elsewhere in this table (CNTB's second row), or the readout itself is a conference poster of 'emerging'/interim data rather than a definitive powered topline (CNSY). C = runway_vs_catalyst reads EXPIRED, SHORT or TIGHT -- a financing event is plausible before or around the date (BIVI, OSTX, ALZN, CUE). D = a specific negative signal surfaced in the note itself -- here, RNTX alone, which stacks a prior partial clinical hold, a catalyst_date_text/note date conflict ('Q3 2026' vs the note's own 'H2 2026'), and a runway figure its own note directly contradicts.
Run 2026-08-07 catalyst dates 2026-10 to 2027-06▾
Screening only, per framework/06-prompts.md § Triage and framework/02-connectors.md § Triage pass. No claim here may enter an analysis without being re-verified there.
Companies searched
Filters used
market cap max $3B; stage/event: Phase 2 data readout
Missing data
- fetch_all_upcoming_catalysts was used as the stage-and-date pre-filter over drug ids per 02-connectors.md § Triage pass step 2. The feed terminated NATURALLY at 788 unique rows (offset 1000 and 1250 both returned empty) rather than at a page cap, so it is treated as complete for this run -- but this is an inference from two empty pages, not a documented guarantee, and a qualifying Phase 2 readout entirely absent from this calendar feed would not have been reachable by the id-join path in step 3. The KARD/Danicamtiv near-miss (see connector_bugs_observed) shows this blind spot is not merely theoretical even when the company itself was correctly identified via its sibling programs.
- The stage_label filter was drawn narrowly: only 'Phase 2', 'Phase 2a' and 'Phase 2b' were kept as 'Phase 2 data readout' per the caller's filter. Combined-phase trials labelled 'Phase 1/2' or 'Phase 2/3' were excluded even where their event_label was 'Data readout' and the date sat inside the window (examples logged in 'excluded' below). A caller who intended those combined-phase trials to count would need a re-run with a broader stage_label list.
- No market-cap floor was applied, since the caller specified none. Rows below include micro-caps under $10M (CRIS at $8.9M, JUNS at $4.4M, SXTP at $3.2M, OGEN at $2.4M).
- Triage does not call CT.gov, PubMed, Open Targets, ChEMBL or web search. Every catalyst date, enrollment figure and safety note below is BPIQ's own, read only against the note field in the same record -- none of it is independently verified and none of it is citable in an analysis without being re-checked there.
- 'slips' was counted qualitatively from reading each company's note changelog during the per-ticker sweep, the same method the 2026-08-04 Phase 3 screen used, rather than a mechanical string-diff. A second reviewer counting the same note text could reasonably differ by one slip on a handful of rows; 0 is reported wherever the guided date was not observed to change across the updates actually read.
Data errors seen in the data connectors
- fetch_all_upcoming_catalysts ignored start_date/end_date exactly as 02-connectors.md documents: requested 2026-10-01..2027-06-30, the first page returned rows starting 2026-08-13, ascending by catalyst_date from a fixed point that includes already-past-dated rows near the front and a long null-catalyst_date tail at the end. Paged and filtered client-side throughout.
- fetch_all_upcoming_catalysts returns no ticker and no market cap on any row, so it cannot screen companies -- used only as a stage/date id pre-filter, exactly as prescribed.
- catalyst_date is synthesized from period text on the large majority of qualifying rows (e.g. 'H2 2026' -> 2026-12-31, 'Late 2026' -> 2026-12-31, 'Early Q4 2026' -> 2026-11-15, 'Mid-2027' -> 2027-08-15, 'Early Q1 2027' -> 2027-02-15). Only 8 of 95 rows name a day or a specific month in catalyst_date_text; all others carry PERIOD precision and the synthesized date should not be read as a real commitment.
- A single BPIQ drug id can be missing from a company's own furthest_drug/next_drug_catalyst/next_bigmover_drug_catalyst join fields even when its sibling programs at the same company DO join correctly: Kardigan (KARD) drug id 20587 (Danicamtiv) did not resolve via the direct id join, and was only recovered because fetch_company_drugs was called on KARD anyway for its two sibling qualifying programs (20585, 20586). A ticker resolved for any reason should always have fetch_company_drugs called on it in full, not just for the specific id that triggered the resolution.
- Two BPIQ drug ids (20409 and 20413, both 'Rapamycin/Sirolimus (LAM-001)' in bronchiolitis obliterans syndrome at QNCX) describe the same trial, same catalyst_date, same catalyst_date_text -- a duplicate-row pattern distinct from the documented 'one row can cover two genuinely different trials' bug. Both are kept in 'ranked' per the output rule (every row from fetch_company_drugs is published), with the duplicate flagged in its own comment and given tier D so it is not read as an independent second event.
- cash_runway_end_date carries far-future sentinel-pattern values beyond the documented 2126-03 case: 2125-06 (IMAB), 2049-10 (PHAT), 2045-11 (KROS), 2041-06 (FGEN), 2035-03 (RAPP), 2030-07 (PHAR), 2030-11 (SNSE), 2029-05 (NKTR), 2028-xx (several). Only years >= 2100 were treated as the not-applicable sentinel here, consistent with 02-connectors.md's stated 2126-03 example; the 2028-2049 values were treated as genuine (if perhaps optimistic) runway figures, not sentinels, since no documented bug covers that range and second-guessing them would be a guess, not a finding.
Left out
- IDYA (16776) — Darovasertib — IDEAYA Biosciences is above the $3B cap (not in the 570-ticker universe); resolved via catalyst_source URL company name.
- DNTH (19223) — Claseprubart (DNTH103) — Dianthus Therapeutics is above the $3B cap.
- TEVA (18444) — Emrusolmin / TEV-286 — Teva is a mega-cap, far above the $3B cap.
- N/A (20587) — Danicamtiv (KINSHIP-DCM) -- initial pass only — catalyst_source was a raw SEC EDGAR S-1/A filing URL with no company name to parse; treated as an unresolved pre-IPO filer in step 3, then recovered in step 4 once ticker KARD was known from its two sibling Kardigan programs and included in 'ranked' -- kept here only to document the method's initial miss.
- ALKS (18685) — ALKS 2680 (RDC-264177) — Alkermes is above the $3B cap.
- N/A (20545) — Velinotamig (BCMAxCD3) -- Autoimmune Cytopenias — stage_label is 'Phase 1/2', a combined-phase trial excluded by this run's narrow reading of 'Phase 2 data readout' (see coverage_gaps).
Legend
- precision:
- DAY = catalyst_date_text names a day. MONTH = names a month or season. PERIOD = half, quarter or year only (including a quarter modified by 'early'/'late'/'mid'); catalyst_date is synthesized by BPIQ.
- slips:
- Count of distinct changes to the guided timing visible in the note changelog actually read during this sweep. 0 means the guidance was stable across the updates read, not that no changelog exists.
- runway_vs_catalyst:
- EXPIRED = cash_runway_end_date is more than ~1 month before the catalyst. SHORT = up to ~1 month before. TIGHT = within ~1 month after. OK = comfortably after. N/A = null or a far-future sentinel (year >= 2100, extending the documented 2126-03 example).
- tier:
- A = clean, funded, materially binary for the company reading it out, no specific red flag surfaced in the sweep. B = a real readout but diluted materiality: multi-asset company (>10 assets), a correlated/sister program at the same company already counted elsewhere in this table, an investigator-initiated or partner-run trial, or a label-expansion trial on an already-approved, revenue-generating product. C = cash_runway_end_date falls at or before the catalyst per runway_vs_catalyst (EXPIRED/SHORT/TIGHT) -- a financing event is plausible before or around the date. D = a specific negative signal surfaced in the note itself (a missed prior endpoint, a discontinued cohort, a partial clinical hold, funding contingent on finding a partner) or the row is a literal duplicate of another row in this table.
Run 2026-08-04 catalyst dates 2026-10 to 2027-06▾
Screening only, per framework/06-prompts.md § Triage and framework/02-connectors.md § Triage pass. No claim here may enter an analysis without being re-verified there.
Companies searched
Filters used
market cap max $3B, Phase 3 data readout
Missing data
- A Phase 3 readout inside the window that is absent from the fetch_all_upcoming_catalysts feed would not be reachable by this method. The feed terminated naturally at 750 rows rather than at a page cap, so it is treated as complete, but this is an assumption, not a verified fact.
- No market-cap floor was applied, since the caller specified none. Rows below include a $2M shell (MBRX).
- Triage does not call CT.gov, PubMed, Open Targets, ChEMBL or web search. Every catalyst date below is BPIQ's own, cross-checked only against the note field in the same record.
Data errors seen in the data connectors
- fetch_all_upcoming_catalysts ignored start_date/end_date: requested 2026-10-01..2027-06-30, first page returned rows from 2026-07-31. Confirms 02-connectors.md. Paged and filtered client-side.
- fetch_all_upcoming_catalysts returns no ticker and no market cap, so it cannot screen companies. Used only as a stage/date filter over drug ids.
- catalyst_date is synthesized from period text on 44 of 51 qualifying rows (e.g. 'H2 2026' -> 2026-12-31, 'H1 2027' -> 2027-06-30, 'Early 2027' -> 2027-02-15). Only CMPX 17398 names a day.
- cash_runway_end_date returns a 2126-03 sentinel for VTVT, XOMA, HRMY and PCRX. Treated as not-applicable, not as a 100-year runway.
- BPIQ ticker RNA is Atrium Therapeutics, not Avidity Biosciences. Avidity (del-desiran, drug id 15268) is above $3B and is out of scope.
- The BPIQ MCP server disconnected mid-sweep and reconnected; the 7 tickers outstanding at that point (CGEM, HRMY, BHVN, VNDA, RARE, PCRX, HCM) were fetched after reconnect. No row below is unverified.
Left out
- ETNB (13548) — pegozafermin in MASH — Acquired by Roche 2025-10-30 per the row's own note. No independent equity to trade.
Legend
- precision:
- DAY = catalyst_date_text names a day. MONTH = names a month or season. PERIOD = half, quarter or year only; catalyst_date is synthesized.
- slips:
- Count of distinct changes to the guided timing visible in the note changelog. 0 means the same guidance was repeated unchanged.
- runway_vs_catalyst:
- EXPIRED / SHORT = cash_runway_end_date falls before the catalyst. TIGHT = within ~1 month after. OK = comfortably after. N/A = null or the 2126-03 sentinel.
- tier:
- A = pivotal binary for this company, credible date, funded through the readout. B = real readout but diluted materiality (partner-run, multi-asset, or revenue-generating). C = financing forces a raise at or before the event. D = the row's date label conflicts with its own note; likely not a readout in this window.